10x Genomics (TXG) Tops Q4 EPS by 4c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
10x Genomics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 Revenue Guidance
February 18, 2020 4:02 PM ESTFull year 2019 revenue growth of 68% over prior year
PLEASANTON, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today reported financial results for the fourth quarter and full year ended December 31, 2019.
Recent Highlights
Revenue of $75.3 million for the fourth quarter and $245.9 million for the full year of 2019, representing 49% and 68% increases, respectively, over the corresponding periods of 2018Total of 1,666 Chromium instruments sold as of December 31, 2019Initiated shipments of the Visium Spatial Gene Expression SolutionFourth Quarter 2019 Financial Results... More
